IP101.

Comparison and Short-term Outcomes in Patients Undergoing Axillobifemoral and Axillounifemoral Bypass Graft
Goran Tesic, Chenee Arthelma Tyson, Saqib Zia, Jonathan Schor, Jonathan Deitch, Kuldeep Singh. Staten Island University Hospital, New York, NY Objectives: Axillofemoral bypass is traditionally used as an alternative for aortoiliac occlusive disease. Typically axillobifemoral bypass (ABFB) is used as the procedure of choice; however, a comparison of axillounifemoral (AUFB) and ABFB is not well studied.
Methods: We queried the National Surgical Quality Improvement Program database for all patients that underwent AUFB (Current Procedural Terminology 35521) and ABFB bypass (Current Procedural Terminology 35654) performed between 2005 and 2011. We reviewed demographics, comorbidities, and 30-day outcomes. We excluded all emergency cases and all cases performed with a venous conduit. Patient demographics, comorbidities, smoking, graft failures, blood transfusions, steroid use, wound infections, failure to wean, and myocardial infarction were compared between groups using c 2 and t-test as appropriate.
Results: There were 595 patients who underwent ABFB and 96 patients in the AUFB group. Patients in AUFB group were a mean age of 68 vs 66 in the ABFB group. There were 60 male patients (62.5%) and 36 female patients (27.5%) recorded in the AUFB group, and 283 male (47.5%) and 312 female patients (52.5%) comprised the ABFB group. Primary outcomes examined were 30-day graft failure and wound infection. There was a significant difference (P ¼ .01) in short-term graft failure comparing ABFB (2.6%) and AUFB (9.1%). A significant difference (P ¼ .03) was also found when comparing the two groups in terms of wound infection occurrences within 30 days, ABFB (33.1%) and AUFB (55%). We also assessed risk factors and perioperative occurrences such as smoking (ABFB 54% vs AUFB 34%; P < .05), diabetes (ABFB 25% vs AUFB 29%; P ¼ .38), blood transfusion (AUFB 0% vs ABFB 2.2%; P ¼ .23), failure to wean from ventilation (AUFB 3.1% vs 8.4%; P ¼ .09), myocardial infarction (AUFB 2.1% vs ABFB 2.7%; P ¼ 1.0), acute renal failure (AUFB 1% vs ABFB 0.2%; P ¼ .26), and steroid use (AUFB 5.2% vs ABFB 3.9%; P ¼ .57).
Conclusions: We noted a significant difference between AUFB and ABFB short-term outcomes with regards to graft failure and wound infection. Results are favoring ABFB, despite increased complexity of the procedure and additional incisions that would favor risk of wound infection. Further studies are needed to elucidate causality and dynamics which apply.
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Objectives: Fenestrated endovascular aneurysm repair (FEVAR) is an alternative to treat complex abdominal aortic aneurysms that involve at least one of the visceral vessels. Patency of visceral vessels remains >90% when covered stents are used. The use of distal uncovered stents to prevent kinking has been reported to be an independent predictor of loss of branch patency. The aim of this study was to evaluate branch related outcomes of FEVAR using covered stents only vs the use covered and distal uncovered stents.
Methods: During a 4-year period, 139 patients (115 men [83%], and 24 women [17%]) underwent FEVAR using Zenith Fenestrated AAA Endovascular Grafts (57%), Zenith P-Branch (4%), and fenestrated premanufactured custom-made devices (39%). Patients with suprarenal, juxtarenal, and type IV thoracoabdominal aneurysms were included. Patients treated with side branched devices were excluded. Covered iCAST stents were used as bringing stents in all cases. Uncovered stents were used distally to the covered stents in 33 patients (24%). Primary end points were primary patency, defined as the absence of occlusion that required intervention. Secondary outcomes were technical success, branchrelated reinterventions, and mortality.
Results: Median age was 72 years (interquartile [IQR] , 67-78 years) for the entire cohort with a median aneurysm size of 56 mm (IQR, (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) . The median number of fenestrations was 3 (IQR, 3-4). In total, 442 target vessels were provided with 49 scallops and 393 fenestrations. Uncovered stents were used in 36 visceral vessels. Median follow-up time was 8 months (IQR, 1.5-13 months). Technical success was obtained in 440 arteries (99%). Overall, visceral vessel primary patency was 90% at 12 months and 75% at 24 months. The overall primary patency rate was 95% at 12 months and 70% at 24 months in the covered/uncovered stent group vs 91% at 12 months and 75% at 24 months when only covered stents were used (P ¼ . 9). Similarly, the rate of branch related reinterventions rate at 24 months was 15% for both groups (P ¼ .8). Patient mortality rate at 24 months was 15% for the covered/uncovered stents group vs 12% for the only covered stents group (P ¼ .3).
Conclusions: The use of distal uncovered stents to prevent kinks was not associated to decreased early branch patency. The long-term outcomes of distal uncovered stents remain to be determined. For now, the use of uncovered stents distal to covered stents may be considered to prevent kinks in complex branch anatomy.
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